Results 21 to 30 of about 5,973 (205)

Propafenone: A Novel Type Ic Antiarrhythmic Agent

, 1989
Propafenone is an investigational type Ic antiarrhythmic agent that markedly slows conduction velocity in all cardiac tissues. Propafenone also possesses weak beta- and calcium-channel blocking properties.
Patrick L. McCollam, Jerry L. Bauman, Robert B. Parker   +2 more
core   +1 more source

Clinically Suspected Myotonic Dystrophy in Sub-Saharan Africa: A Rare Case Report Highlighting Rehabilitation Challenges. [PDF]

Clin Case Rep
ABSTRACT Myotonic dystrophy is an autosomal dominant multisystem disorder rarely reported in sub‐Saharan Africa. We report a 30‐year‐old Ethiopian female with progressive weakness, myotonia, positive family history, and characteristic electromyography findings. As there is no curative treatment, management is supportive. This case highlights its rarity
Abie AS, Gizaw S, Berhe T, Yibe B, Elias TP.   +4 more
europepmc   +2 more sources

Clinical pharmacology of propafenone.

, 1983
We determined the efficacy, pharmacokinetics, and plasma concentration-response relationships of propafenone, a promising new antiarrhythmic drug. Thirteen patients with frequent and complex ventricular premature beats were studied after receiving four ...
D C Harrison, S J Connolly, C S Lebsack, R E Kates, R A Winkle   +4 more
core   +1 more source

Propafenone: A new agent for ventricular arrhythmia [PDF]

, 1984
Propafenone, a new antiarrhythmic agent, was utilized in 30 patients with diverse heart disease who presented with sustained hemodynamically unstable ventricular arrhythmia.
Lown, Bernard, Podrid, Philip J.
core   +1 more source

Comparison of antiarrhythmic medications propafenone and amiodarone injection forms effectiveness in medicamentous cardioversion of paroxysmal atrial fibrillation

, 2019
Background. According to present 2016–2017 recommendations, propafenone and amiodarone are the main antiarrhythmic medications (AAM) for medicamentous sinus rhythm (SR) restoration.
Sergei A. Kosykh, Karapet V. Davtyan, Elena V. Bushueva, Olga N. Miller, Aleksei V. Tarasov   +4 more
core   +1 more source

Stereoselective disposition and pharmacologic activity of propafenone enantiomers.

, 1989
Propafenone is an antiarrhythmic drug that produces a variable degree of beta-blockade in humans and is administered as a racemate. To examine the relative contribution of the individual enantiomers to pharmacologic effects seen during treatment with ...
R L Woosley, A J Wood, D M Roden, D J Silberstein, C Funck-Brentano, H K Kroemer, M Eichelbaum   +6 more
core   +1 more source

Detoxification effects of long-chain versus a mixture of medium- and long-chain triglyceride-based fat emulsion on propafenone poisoning

Brazilian Journal of Medical and Biological Research
In the present study, we aimed to compare the detoxifying effects of two fat emulsions containing either long-chain triglyceride or a mixture of medium-chain and long-chain triglycerides in the propafenone-poisoned rat model.
Xusheng An, Yong Mei, Hao Sun, Jinsong Zhang   +3 more
doaj   +1 more source

“Pill-in-the-Pocket” Treatment of Propafenone Unmasks ECG Brugada Pattern in an Atrial Fibrillation Patient With a Common SCN5A R1193Q Polymorphism

Frontiers in Physiology, 2019
Background: “Pill-in-the-pocket” (PIP) treatment with type IC drugs for cardioversion of recent-onset atrial fibrillation (AF) has been recommended in guidelines.
Linling Li, Yanfei Ruan, Nian Liu, Qianqian Zhao, Mengxia Zhang, Xin Li, Song Zuo, Jiang Le, Kui Wu, Rong Bai, Changsheng Ma   +10 more
doaj   +1 more source

Research Progress of Berberine in Kidney Disease: Targeting Mitochondria and Ferroptosis

iNew Medicine, EarlyView.
This figure illustrates the model‐specific renoprotective mechanisms of berberine (BBR) across three major kidney diseases. From left to right, the diagram shows that BBR targets distinct core pathways depending on the pathological context: in diabetic nephropathy (DN), BBR activates AMPK to improve mitochondrial energy metabolism; in acute kidney ...
Liuqing Wang, Rongyu Guo, Xiaojun Feng, Liqin Tang   +3 more
wiley   +1 more source

Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy

, 1990
We evaluated the antiarrhythmic efficacy and the minimal effective concentrations of propafenone and its metabolite 5-hydroxy-propafenone during a) acute intravenous infusion (1.5 mg/kg in bolus followed by 45 minutes infusion), b) an acute oral single ...
FRABETTI L, STROCCHI E, MAGNANI B., CAPUCCI A, BORIANI, Giuseppe, AMBROSIONI E, MARCHESINI B, BALDUCELLI M, TOMASI L   +8 more
core   +1 more source